FANCB/BRCA2,乳腺癌易感基因2抗体

产品编号HZ-1210R
英文名称FANCB/BRCA2
中文名称乳腺癌易感基因2抗体
别 名BRCA 2; BRCA1/BRCA2 containing complex subunit 2; BRCC 2; BRCC2; Breast and ovarian cancer susceptibility gene early onset; Breast cancer 2 early onset; Breast Cancer 2 tumor suppressor; Breast cancer susceptibility protein BRCA2; Breast cancer type 2 susceptibility protein; FACD; FAD 1; FAD; FAD1; FANCB; FANCD 1; FANCD; FANCD1; Fanconi anemia complementation group D1; Fanconi anemia group D1 protein; OTTHUMP00000018803; OTTHUMP00000042401.
说 明 书0.1ml 0.2ml
研究领域肿瘤 细胞生物 免疫学
抗体来源Rabbit
FANCB/BRCA2,乳腺癌易感基因2抗体克隆类型Polyclonal
交叉反应Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Rabbit,
产品应用ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量384kDa
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthetic peptide derived from human BRCA2
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
FANCB/BRCA2,乳腺癌易感基因2抗体PubMedPubMed
产品介绍background:
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group B. Alternative splicing results in two transcript variants encoding the same protein. [provided by RefSeq, Jul 2008]

Function:
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication.

Subunit:
Monomer and dimer. Interacts with RAD51; regulates RAD51 recruitment and function at sites of DNA repair. Interacts with DSS1. Interacts with both nonubiquitinated and monoubiquitinated FANCD2; this complex also includes XRCC3 and phosphorylated FANCG. Interacts with WDR16. Interacts with USP11. Interacts with DMC1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2. Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein. Interacts with ROCK2 and NPM1.

Subcellular Location:
Nuclear protein.

FANCB/BRCA2,乳腺癌易感基因2抗体Tissue Specificity:
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.

Post-translational modifications:
Phosphorylated by ATM upon irradiation-induced DNA damage. Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51. Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51 binding.
Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation.

DISEASE:
Defects in BRCA2 are a cause of susceptibility to breast cancer (BC). A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Similarity:
Contains 8 BRCA2 repeats.

Gene ID:
2187

Database links:
Entrez Gene: 2187 Human
Omim: 300515 Human
SwissProt: Q8NB91 Human
Unigene: 554740 Human

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.